INTRODUCTION

Retinoblastoma (Rb) is the most common primary intraocular malignancy of the neurosensory retina accounting for approximately 3% of childhood malignancies. Its incidence is between 1:17,000 - 1:20,000 live births and approximately 7000-8000 cases are reported per annum. It exclusively affects infants and young children and shows no significant race or gender predilection. According to World Health Organization (WHO), 66% cases are detected...
before 24 months whereas approximately 95% cases are seen before five years of age. Local literature reports the incidence to be 4 and 2.4 in 100,000 children before age five and ten respectively. In Asia-Pacific region, India reports highest number of Rb cases while Pakistan ranks sixth.

Retinoblastoma is primarily a clinical diagnosis and histological evaluation of enucleated eyes for the presence of high risk factors is important in deciding further treatment including adjuvant chemotherapy. Histological presence of high risk factors (HRFs) can predict local recurrence, distant metastases, tumor progression and overall prognosis. HRFs such as choroidal, scleral, extrascleral, and optic nerve invasion (posterior to lamina cribrosa or up to the cut end of the optic nerve) are predictors of metastases.

Incidence of HRFs and systemic metastases is reported to be less in high income countries; the reason being early presentation, diagnosis and treatment as compared to advanced-stage disease presentation in developing countries due to lack of education, low socioeconomic status and lack of access to health care facilities.

Treatment of retinoblastoma depends on various factors including laterality and stage of disease. Chemotherapy along with local therapies like brachytherapy, cryotherapy and laser can be used to salvage eyes with early intraocular disease. Despite of advancement seen in early diagnosis and treatment of retinoblastoma, its management still remains a challenge in developing countries. This study assesses the frequency of HRFs in enucleated eyes which would be helpful in deciding future management of the patients.

METHODS

A cross-sectional observational analysis was performed on enucleated eye specimens of all patients who had a clinical diagnosis of intraocular retinoblastoma presenting to our institute between September 2017 and February 2021.

Ethical Approval: The study participants were enrolled after approval from the ethics review board of the institute (IHHN_IRB_2021_03_007) in accordance to the guidelines of Declaration of Helsinki and an exemption was provided due to retrospective nature of the study. Treatment naïve retinoblastoma patients <18 years and of either gender were included in the study.

Patient demographics included age and gender. Tumor characteristics included laterality, size of tumor, histologic grade, anaplasia grade, growth pattern (exophytic or endophytic), extent of optic nerve (ON) invasion, pathologic staging, tumor involvement of ocular structures, and additional findings (calcification, necrosis, inflammation, hemorrhage). Histologically, well differentiated tumors (G1) contained areas of retinocytoma (neuronal differentiation or fluorettes), moderately differentiated tumors were tumors with many Flexner-Wintersteiner or Homer-Wright rosettes (G2), or occasional Flexner-Wintersteiner or Homer-Wright rosettes (G3), while poorly differentiated (G4) tumors lacked any evidence of rosettes formation and/or extensive anaplasia (>50%). Endophytic growth pattern indicated growth from the inner retinal surface into the vitreous cavity while exophytic tumors grew primarily from the outer surface of the retina into the subretinal space toward the choroid. Combined growth pattern exhibited features of both endophytic and exophytic growth.

High-risk factors:

1. Anterior chamber invasion involving iris, ciliary body (Fig.1A)
2. Choroidal invasion (Fig.1B):
   a. Massive: >3 mm in diameter and/or with the full thickness of choroidal involvement.
   b. Minimal: ≤3 mm in diameter and with partial-thickness of choroidal involvement.
3. The optic nerve invasion posterior to lamina cribrosa & to the transection line of the nerve (Fig.1C).
4. Scleral or extrascleral involvement (Fig.1D).

Statistical Analysis: The statistical analysis was performed using SPSS version 24.0. Continuous parameters such as age and size of tumor were represented by median (interquartile range) or mean ± SD depending on the normality while categorical parameters such as gender, laterality, histologic grade, anaplasia grade, growth pattern, extent of optic nerve invasion, pathologic staging, tumor involvement of ocular structures and additional findings were represented in proportions. The categorical data were compared using Chi-square (Fisher exact) test as per the need. A p-value of <0.05 was considered statistically significant.

RESULTS

The study included 54 patients of retinoblastoma during the study period. The median age at presentation was 24 months (IQR: 18-36 months). Female preponderance i.e. 53.7% was observed. Review of enucleated eyes with retinoblastoma revealed following histopathological features and high-risk factors (Table-I). Comparison of various factors with degree of differentiation of tumor is displayed in...
(Table-II). Certain ocular features could not be assessed in few cases due to non-visualisation of these structures as a result of extensive tumor necrosis.

**DISCUSSION**

Enucleation is one of the oldest forms of treatment for retinoblastoma particularly in advanced cases and considered as the best treatment option for patients with unilateral disease and non-salvageable HRFBs in retinoblastoma.

| Table-I: Histopathological features of retinoblastoma |
|------------------------------------------------------|
| **Variables**                                         | **Values**                 |
| Laterality:                                          |                            |
| Unilateral, n (%)                                    | 50 (92.6)                  |
| Bilateral, n (%)                                     | 4 (7.4)                    |
| Tumor size, cm                                       | 1.7 (1.5-2.0)              |
| Histologic grade (n=51)                              |                            |
| Well-differentiated (G1), n (%)                      | 4 (9.8)                    |
| Moderately differentiated (G2), n (%)                | 34 (64.7)                  |
| Moderately differentiated (G3), n (%)                | 11 (21.6)                  |
| Poorly differentiated (G4), n (%)                    | 2 (3.9)                    |
| Could not be determined, n (%)                       | 3                          |
| Anaplasia grade (n=49)                               |                            |
| Mild, n (%)                                          | 20 (40.8)                  |
| Moderate, n (%)                                      | 29 (59.2)                  |
| Severe, n (%)                                        | 0                          |
| Growth pattern (n=53)                                |                            |
| Endophytic, n (%)                                    | 41 (77.4)                  |
| Exophytic, n (%)                                     | 7 (13.2)                   |
| Combined endophytic and exophytic, n (%)             | 5 (9.4)                    |
| Tumor involvement of other ocular structures:        |                            |
| Vitreous, n (%)                                      | 45/52 (86.5)               |
| Optic nerve head, n (%)                              | 24/31 (77.4)               |
| Sub-retinal pigment epithelial space, n (%)          | 17/27 (63.0)               |
| Sub-retinal space, n (%)                             | 29/47 (61.7)               |
| Optic disc, n (%)                                    | 8/20 (40.0)                |
| Cornea, n (%)                                        | 1/53 (3.8)                 |
| Optic nerve invasion (n=36)                          |                            |
| Anterior to lamina cibroisa, n (%)                   | 15 (41.6)                  |
| At lamina cibroisa, n (%)                            | 5 (13.9)                   |
| Posterior to lamina cibroisa, n (%)                  | 15 (41.6)                  |
| Up to transection line of ON, n (%)                  | 1 (2.8)                    |
| Pathologic staging (n=51)                            |                            |
| pT1, n (%)                                           | 20 (39.2)                  |
| pT2, n (%)                                           | 1 (2.0)                    |
| pT2a, n (%)                                          | 12 (23.5)                  |
| pT3, n (%)                                           | 4 (7.4)                    |
| pT3b, n (%)                                          | 10 (19.6)                  |
| pT3d, n (%)                                          | 1 (2.0)                    |
| pT4, n (%)                                           | 2 (3.9)                    |
| Additional findings:                                |                            |
| Necrosis, n (%)                                      | 44/50 (88.0)               |
| Calcification, n (%)                                 | 32/51 (62.7)               |
| Inflammation, n (%)                                  | 21/54 (38.8)               |
| Haemorrhage, n (%)                                   | 7/54 (12.9)                |
| Retinal detachment, n (%)                            | 2/54 (3.7)                 |
| High-risk factors                                    |                            |
| Anterior segment structures involvement (n=53)       |                            |
| Iris, n (%)                                           | 2 (3.8%)                   |
| Ciliary body, n (%)                                  | 2 (3.8%)                   |
| Choroidal invasion (n=18)                            |                            |
| ≤3mm, n (%)                                          | 10 (55.6)                  |
| >3mm, n (%)                                          | 8 (44.4)                   |
| Extent of optic nerve invasion (n=20)                 |                            |
| Posterior to lamina cibroisa, n (%)                  | 15 (75.0)                  |
| Up to transection line of the nerve, n (%)           | 1 (5.0)                    |
| Scleral invasion, n (%)                              | 4/54 (7.4)                 |
| Extrascleral invasion, n (%)                         | 1/54 (1.9)                 |

Fig.1
vision. Enucleated eyeball is always assessed for the presence of HRFs. Presence of HRFs warrants the risk of secondary orbital recurrence as well as systemic metastasis, and thus there is a strong indication of adjuvant treatment comprising of chemotherapy and/or External Beam Radiation Therapy (EBRT) which resulted in risk reduction of metastasis to 4% in comparison to 24% who did not receive the treatment according to Honovar et al.11 Histopathological features of retinoblastoma have been the focus of many studies.6-8,12,13 The present study assessed the histopathological features of retinoblastoma with an emphasis on the high-risk factors. Mean age of presentation in the present study was 29.15 ± 18.20 months (Median – 24; IQR-18.0 – 36.0 months) which was similar to findings of other regional studies by Zia et al14, and Gupta et al.12 also reported that age at presentation greater than 24 months was a predictor for HRFs. In our study, HRFs were noted in 24.0% patients who presented at >24 months of age.

The present study reports presence of well-differentiated tumors in patients who presented at age <24 months in comparison to poorly differentiated tumors who presented in older age group (Table-II). Kashyap et al.15 also reported poorly differentiated tumors in patinets presenting at an age of >24 months. Present study also reported presence of HRFs in tumors which showed poor differentiation (Table-II) This was similar to another study in which multiple HRFs were observed in poorly differentiated tumors (26%) in comparison to well-differentiated tumors (6.7%).15

The HRFs include optic nerve invasion (posterior to lamina cribrosa or to the cut end of the nerve), choroidal, scleral, and extrascleral involvement. The number of patients with ≥1 HRFs in the present study was 35.2% which was similar to the prevalence reported by Kaliki et al.13 i.e. 38%. Our study reported 1 HRF and >1 HRF in 18.5% and 16.7% patients respectively which was in concordance to a study by Kashyap et al.15 which reported 18.7% and 22.7% patients for the same. These HRFs have been reported to have a varying prevalence i.e. 6%-28% for invasion of optic nerve posterior to lamina cribrosa and optic nerve to the resection line, 12%-42% for choroidal involvement and 8%-15% for scleral and extrascleral spread.9 Comparison of the frequency of HRFs observed in our study was compared with other studies from nearly two decades as displayed in Table-III.

The extent of optic nerve invasion is one of the HRFs with incidence of metastasis being reported in 12%-42%9 cases involving posterior to lamina

| Degree of tumor differentiation | Number of HRF | Presence of HRF | Laterality | Age categories |
|-------------------------------|--------------|----------------|------------|---------------|
|                               | No HRF | 1 HRF | 2 HRF | 3 HRF | p-value | No HRF | 1 HRF | >1 HRF | p-value | Unilateral | Bilateral | p-value | <24 months | >24 months | p-value |
| Well differentiated (G1); n=4   |        |      |      |      |         |        |      |        |      |          |          |          |          |            |            |          |
|                               | 3 (75) | 1 (25) | 0 | 0 |         | 3 (75) | 1 (25) |         | 3 (75) | 1 (25) | 3 (75) | 1 (25) |          |            |            |          |
| Moderately differentiated (G2); n=33 |  |      |      |      |         |        |      |        |      |          |          |          |          |            |            |          |
|                               | 21 (61.8) | 7 (20.6) | 6 (17.6) | 0 |         | 21 (61.8) | 13 (38.2) | 31 (91.2) | 3 | 21 (61.8) | 13 (38.2) |          |            |            |          |
| Moderately differentiated (G3); n=11 |  |      |      |      |         |        |      |        |      |          |          |          |          |            |            |          |
|                               | 7 (63.6) | 2 (18.2) | 1 (9.1) | 1 (9.1) |         | 7 (63.6) | 4 (36.4) | 11 (100) | 0 |           |           | 4 (36.4) | 7 (63.6) |            |            |          |
| Poorly differentiated (G4); n=2 |        |      |      |      |         |        |      |        |      |          |          |          |          |            |            |          |
|                               | 1 (50) | 0 | 1 (50) | 0 |         | 1 (50) | 1 (50) | 2 (100) | 0 |           |           | 0 | 2 (100) |            |            |          |
cribrosa and up to 41%-78% involving transection line.11 In present study, 66.7% of eyes had optic nerve involvement with variable degree of invasion i.e. both anterior and posterior to lamina cribrosa. An unusual finding in the present study was a very high prevalence (41.7%) of involvement of optic nerve posterior to lamina cribrosa which was similar to the frequency reported by Kaliki et al. (49%)16 and Orellana et al. (39.6%)8 (Table-III). The higher frequency of optic nerve involvement were all reported from low middle income countries and thus could be attributed to the fact that patients present at advanced stage of disease due to lack of access to health care facilities while another reason could be lack of awareness among parents and health care providers at primary health care level.

In present study, frequency of choroidal involvement was 33.3% out of which massive invasion of choroid was present in 44% cases. This observation of massive choroidal involvement was similar to the frequency reported by Orellana et al.8 i.e. 41.3% but was much higher to an Indian study which reported 27.5% cases with choroidal invasion.9 Choroidal involvement is considered to be a high risk factor for metastases particularly if seen in association with optic nerve involvement.9 The involvement of anterior chamber structures i.e. iris and ciliary body also constitutes a HRF. The present study reported the involvement of iris and ciliary body in 3.7% cases each. This finding was found to be similar to the reported frequencies of ciliary body (4.7%) and iris (4.7%) involvement in an Indian study by Kaliki et al.13

Scleral invasion is the invasion of the tumor beyond the choroid. Current study reported the frequency of this HRF in 7.4% cases which was relatively closer to the frequencies reported by various Indian studies.8,12,17 Extrascleral invasion

---

**Table-III: Comparison of studies reporting the prevalence of high-risk factors in retinoblastoma.**

| Study                  | Anterior chamber Iris, n (%) | Ciliary body, n (%) | Choroidal invasion, n (%) | Scleral invasion, n (%) | Extrascleral invasion, n (%) | Retrolaminar ON involvement, n (%) | ON to cut end involvement, n (%) |
|------------------------|------------------------------|---------------------|---------------------------|-------------------------|-----------------------------|-----------------------------------|---------------------------------|
| Biswas et al.7 (n=232; 2003) | NA                           | NA                  | 51 (21.9)                 | NA                      | NA                          | 13 (5.6)                          | NA                              |
| Orellana et al.8 (n=101; 2009) | NA                           | NA                  | 42 (41.5)                 | 9 (8.9)                 | 10 (9.9)                    | 40 (39.6)                         | NA                              |
| Gupta et al.12 (n=142; 2009) | 10 (7)                       | 13 (9)              | 57 (40.1)                 | 13 (9.1)                | 9 (6.3)                     | 24 (16.9)                         | 11 (7.7)                        |
| Kashyap et al.15 (n=609; 2012) | 65 (10.7)                    | NA                  | 150 (24.6)                | 83 (13.7)               | 25 (4.1)                    | 98 (16.1)                         | 45 (7.4)                        |
| Kashyap et al.17 (n=326; 2012) | 29 (9)                       | 23 (7)              | 71 (21.2)                 | 28 (9)                  | 11 (3.4)                    | 54 (17)                           | 18 (5.5)                        |
| Yousef et al.18 (n=50; 2014) | NA                           | 3 (6)               | 9 (18)                    | NA                      | NA                          | 7 (14)                            | NA                              |
| Rao et al.19 (n=17; 2014) | 5 (29.4)                     | 5 (29.4)            | 10 (58.8)                 | 5 (29.4)                | 2 (11.8)                    | NA                                | 4 (23.5)                        |
| Kaliki et al.20 (n=403; 145 cases, 285 controls; 2015) | 12 (8)                       | 17 (12)             | 96 (66)                   | 20 (14)                 | 8 (6)                       | 71 (49)                           | 3 (2)                           |
| Kaliki et al.21 (331 Indians/193 Americans; 2018) | 11 (3.3) / 9 (5)           | 14 (4.2) / 6 (3)     | 57 (17) / 12 (5)          | 19 (5.7) / 3 (2)        | 7 (2.1) / 2 (1)             | 56 (16.9) / 22 (11)               | 2 (0.6) / 1 (0.5)               |
| Yahaya et al.22 (28) (n=234; 2019) | 37 (21.5)                    | 47 (27.3)           | 39 (22.7)                 | NA                      | 67 (28.5)                   | NA                                | NA                              |
| Kaliki et al.23 (n=616; 2020) | 28 (4.5)                     | 29 (4.7)            | 120 (19.5)                | 30 (4.9)                | 10 (1.6)                    | 103 (16.7)                        | 11 (1.8)                        |
| Present study (n=54; 2021) | 2 (3.7)                      | 2 (3.7)             | 18 (33.3)                 | 4 (7.4)                 | 1 (1.9)                     | 15 (41.7)                         | 1 (2.8)                         |

ON=Optic nerve; NA=Not available.
was seen in 1.9% of the patients which was almost the same as the frequency i.e. 1.6% reported by Kaliki et al. as well in the Indian patients cohort which compared the occurrence of HRFs between American and Indian retinoblastoma patients.

Limitations: The short study span and small sample size may be considered as limitations of our study. Presence of high-risk factors in these patients was not further evaluated by follow-up to assess the impact of their presence on disease progression which warrants further research to analyse outcome in context of presence of HRFs.

CONCLUSION

In conclusion, this is a retrospective data analysis of high risk histopathological factors in eyes diagnosed with retinoblastoma and treated with primary enucleation from a low middle income country. As our center is a major tertiary care referral hospital, our results might be highly representative of high risk factors in retinoblastoma in our population. The incidence of HRFs has declined over time in studies from developed countries because of early presentation and diagnosis. However, the same is not seen in studies from the developing world. Late presentation of patients, age >24months, and with more advanced disease result in poor outcome in retinoblastoma.

Source of funding: None to declare.

Financial Disclosures: None to declare.

REFERENCES

1. Fabian ID, Sagoo MS. Understanding Retinoblastoma: Epidemiology And Genetics. Community Eye Health. 2018;31(10):7.
2. Organization WH. Retinoblastoma. Union For International Cancer Control 2014 Review of Cancer Medicines on the WHO List Of Essential Medicines. 2014. Avaiable At: https://www.Who.Int/Selection_Medicines/Committees/Expert/20/Applications/Retinoblastoma.Pdf
3. Adhi MI, Kashfy S, Muhammed K, Siyal N. Clinical Patterns Of Retinoblastoma In Pakistani Population: Review Of 403 Eyes In 295 Patients. J Pak Med Assoc. 2018;68(3):376-380.
4. Jain M, Rojanaporn D, Chawla B, Gopal L, Khetan V. Retinoblastoma Presentation And Survival: A Four-Year Analysis From A Tertiary Care Hospital. Pak J Med Sci 2020;36(1):S61-S66. doi: 10.1155/2020/10.12669/Pjms.36.ICON-Suppl.1720.
5. Kashfy S, Sethi S, Meel R, Pushker N, Sen S, Bajaj MS, et al. A Histopathologic Analysis Of Eyes Primarily Enucleated For Advanced Intraocular Retinoblastoma From A Developing Country. Arch Pathol Lab Med. 2012;136(2):190-193. doi: 10.5858/Apa.2010-0759-OA
6. Kaliki S, Srinivasan V, Gupta A, Mishra DK, Naik MN. Clinical Features Predictive Of High-Risk Retinoblastoma In 403 Asian Indian Patients: A Case-Control Study. Ophthalmology. 2015;122(6):1165-1172. doi: 10.1016/J.Ophtha.2015.01.018
7. Kashfy S, Meel R, Pushker N, Sen S, Bakhshi S, Sreenivas V, et al. Clinical Predictors Of High Risk Histopathology In Retinoblastoma. Pediatr Blood Cancer 2012;58(3):356-361. doi: 10.1002/Pbc.23239
8. Youssef Y, Haja Y, Nawaiseh I, Mehyar M, Sultan I, Deebajah R, et al. A Histopathologic Analysis Of 50 Eyes Primarily Enucleated For Retinoblastoma In A Tertiary Cancer Center In Jordan. Turk Patoloji Derg. 2014;30(3):171-177. doi: 10.5346/Tipath.2014.01260
9. Rao S, Soibi P, Nita Khurana K. High-Risk Histomorphological Features In Retinoblastoma And Their Association With P53 Expression: An Indian Experience. Indian J Ophthalmol. 2014;62(11):1069-1071. doi: 10.4103/0301-4788.146747
10. Yahaya JJ, Rugwizangoga B, Mremi A, Munema A. Clinical Risk Factors In Retinoblastoma Based On Age At Primary Enucleation: A Study Of 616 Eyes. Eye. 2020;34(8):1441-1448.

Authors’ Contribution: NY: Substantial contribution towards the concept of the study, revised it critically for important intellectual content; SM: Drafted the work, revised it critically for important intellectual content; KA, SAH, SJ: Revisied it critically for important intellectual content; BK: Substantially contributed towards data acquisition, analysis, and interpretation; drafted the work; All authors approved the final version and also agreed to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

Authors:

1. Nausheen Yaqoob, FCPS
2. Salima Mansoor, MBBS
3. Saba Jamil, FCPS
4. Bushra Kaleem, MPH (Haematology) Indus Health Research Center
5. Ahmer Hamid, FCPS
6. Department of Paediatric Oncology, Indus Hospital & Health Network, Karachi, Pakistan.

References:

1. Nausheen Yaqoob, FCPS
2. Salima Mansoor, MBBS
3. Saba Jamil, FCPS
4. Bushra Kaleem, MPH (Haematology) Indus Health Research Center
5. Ahmer Hamid, FCPS
6. Department of Paediatric Oncology, Indus Hospital & Health Network, Karachi, Pakistan.